Patients with locally advanced cervical cancer who receive dual checkpoint blockade before standard chemoradiation have high 3-year survival, but outcomes are poorer for those with ‘cold’ tumors.

Around 90 women with advanced cervical cancer in the UK could be eligible for treatment with Regeneron's immunotherapy ...

Hundreds of women with aggressive cervical cancer are to be offered MSD's Keytruda on the NHS in England, in the second ...

A pembrolizumab (Keytruda) combination led to an overall survival (OS) boost in patients with newly diagnosed, previously untreated, high-risk locally advanced cervical cancer, according to results ...

In patients with locally advanced cervical cancer receiving chemoradiation, irradiating less than whole uterus led to a low local recurrence rate and less radiation to the bowel but significantly ...

Share on Pinterest Results from a phase 3 clinical trial show promise for a new standard of care for treating people with advanced cervical cancer. AzmanL/Getty Images A phase 3 clinical trial ...

Study on the efficacy and toxicity of pamiparib combined with tamoxifen in the treatment of patients with epithelial ovarian cancer with biochemical recurrence during first-line PARPi maintenance ...

Cervical cancer patients were significantly more likely to be alive and cancer-free after five years when given a short course of chemotherapy prior to chemoradiation. This is the finding of a ...

The cervical cancer treatment market is expanding rapidly due to rising global disease burden, persistent HPV infection, and advancements in therapies like targeted and immunotherapies. Key ...

First immunotherapy approved for LACC in England offers new treatment option for women MSD has welcomed the National Institute for Health and Care Excellence’s recommendation of pembrolizumab ...

A new University of Kentucky Markey Cancer Center study provides important insights for future clinical trials in treating advanced cervical cancer by establishing a five-month progression-free ...